Avelumab and Merkel Cell Carcinoma: Examining the Scientific Evidence

From General Health Science to Occupational Exposure Concerns

The legacy context of general health and science information has long served as a foundation for public understanding of medical treatments and their biological interactions. Within this broad framework, discussions of therapeutic agents typically emphasize efficacy, safety profiles, and patient outcomes, drawing from established pharmacological principles. This heritage provides a structured approach to evaluating how substances introduced into the body may influence cellular processes over time. Transitioning from this general health perspective to a more focused occupational exposure concern requires careful consideration of how therapeutic compounds enter non-clinical environments. Avelumab, a monoclonal antibody approved for certain oncological indications, represents a case where the boundary between clinical use and potential workplace exposure becomes relevant. In mass production settings, handling of pharmaceutical agents may involve repeated contact through inhalation, dermal absorption, or accidental inoculation, raising questions about long-term biological effects distinct from controlled therapeutic administration. The pivot to occupational exposure thus reframes the inquiry: rather than assessing intended pharmacological action, the concern shifts to unintended consequences of environmental contact with active pharmaceutical ingredients. This transition acknowledges that while general health science provides the baseline understanding of drug mechanisms, occupational health contexts demand separate evaluation of exposure routes, durations, and population susceptibilities that differ markedly from patient populations. The bridge concept therefore connects established pharmacological knowledge with emerging occupational risk assessment frameworks.

Avelumab: Mechanism and Approved Use in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). This approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is characterized by high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Scientific Evidence on Causation: Avelumab as Treatment, Not Cause

The scientific evidence connecting avelumab to Merkel cell carcinoma is primarily in the context of its therapeutic use, not as a causative agent. Avelumab is approved for treating MCC, and the literature describes its efficacy and safety in this patient population. For example, avelumab has been shown to cause immune-related adverse events due to overactivation of the immune system, including a reported case of hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). In that case, hypercalcemia was managed with corticosteroids, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This indicates that while avelumab can trigger immune-mediated adverse events, it is not implicated in causing MCC itself. Mechanistic pathways linking avelumab to MCC are not described in the provided evidence as causal. Instead, the evidence focuses on avelumab's role as a treatment for MCC. The drug's mechanism of action—blocking PD-L1 to enhance T-cell activity against tumor cells—is the basis for its therapeutic effect in MCC. No evidence suggests that avelumab induces or promotes the development of MCC. Rather, the drug is used to treat existing MCC, and its adverse effects are related to immune activation, not carcinogenesis.

Risk Considerations and Patient Management

Risk considerations for affected patients include the adequacy of warnings regarding avelumab and MCC. The evidence indicates that avelumab is approved for MCC treatment, and its prescribing information likely includes warnings about immune-related adverse events, as seen in the sarcoidosis case (https://pubmed.ncbi.nlm.nih.gov/31543781/). However, no evidence in the provided snippets addresses specific warnings about avelumab causing MCC. Given that avelumab is a treatment for MCC, causation-related considerations would focus on whether the drug contributed to disease progression or adverse outcomes in patients already diagnosed with MCC. The evidence shows that some patients become refractory to avelumab, and alternative treatments such as ipilimumab plus nivolumab have been studied in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). In one study, three out of five patients with avelumab-refractory MCC responded to combined ipilimumab and nivolumab (https://pubmed.ncbi.nlm.nih.gov/33439294/). This suggests that while avelumab is effective for some, others may not benefit, and subsequent therapies are needed. The timeline between exposure to avelumab and documented harm is not explicitly detailed in the provided evidence. However, the JAVELIN Merkel 200 trial and subsequent studies indicate that avelumab is administered to patients with metastatic MCC, and responses or adverse events occur during treatment. For example, the sarcoidosis-related hypercalcemia case occurred during avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). No evidence suggests a latency period between avelumab exposure and MCC development, as the drug is used to treat an existing cancer. In summary, the scientific evidence does not support a causal link between avelumab and the development of Merkel cell carcinoma. Instead, avelumab is a therapeutic agent for MCC, with documented efficacy and immune-related adverse events. Risk considerations for patients involve monitoring for immune-related adverse events and managing treatment resistance. The adequacy of warnings should include information on immune-related adverse events, but no evidence indicates that avelumab causes MCC.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, the scientific evidence does not support a causal link between avelumab and the development of Merkel cell carcinoma. Avelumab is a therapeutic agent used to treat existing MCC, and its adverse effects are related to immune activation, not carcinogenesis (https://pubmed.ncbi.nlm.nih.gov/29799096/; https://pubmed.ncbi.nlm.nih.gov/31543781/).

What is the evidence for avelumab's role in Merkel cell carcinoma?

Avelumab is approved for treating metastatic Merkel cell carcinoma based on the JAVELIN Merkel 200 trial, which showed objective responses in about one-third of patients (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is not implicated as a cause of MCC; rather, it is a treatment that can cause immune-related adverse events (https://pubmed.ncbi.nlm.nih.gov/31543781/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.